A $40M bet on women's health

Evvy raised a $40 million Series B led by Catalio Capital Management, announced Tuesday. The company was launched in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro.

One swab, sequenced at home

Evvy runs what it calls the only at-home CLIA- and CLEP-certified mNGS test for vaginal microbes. Users mail in a swab, the lab sequences it, and clinicians on the platform review the results.

Results come with a next step

Patients get findings in an online portal alongside a diagnosis and clinical interpretation, not just raw data. Personalized prescription care follows when it applies.

“They are presented alongside a diagnosis, clinical interpretation, and a clear path of next steps”

100,000 patients and counting

Evvy now serves more than 100,000 patients in the US and works with 3,000 practitioners. It claims 15 peer-reviewed publications, novel BV subtypes, and hundreds of previously uncatalogued microbiome genomes.

The real product is the dataset

Treatment is only half the plan. Jain wants a dataset linking microbiome biology, symptoms, interventions, and outcomes into a feedback loop that surfaces entirely new biomarkers.

AI needs new biology

Jain argues precision medicine for women fails because the underlying data never measured female bodies properly, and leading AI models stumble on women's health questions. Her fix is pairing AI with new biological data at scale.

“You can't build precision medicine for women on datasets that never adequately measured female biology in the first place”

Moving into fertility

Evvy is entering fertility, its first big step beyond vaginal health, with research linking the microbiome to infertility, gynecological cancer, preterm birth, IVF success, and recurrent pregnancy loss. A prospective study in IVF clinics launched last year.

“Women shouldn't have to accept unexplained infertility, unexplained recurrence, or unexplained symptoms as answers”

A new-age Pap smear

The long game is an at-home, non-invasive sample giving regular insight across infections, inflammation, fertility, PCOS, endometriosis, perimenopause, and HPV progression. Rivals include Juno Bio, Tiny Health, and Daye.

“I don't think we can wait for traditional research methods to catch up”